New treatment approach for advanced pancreatic cancer
TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer
This study is testing a new treatment for advanced pancreatic cancer that combines a special chemotherapy drug with immune boosters to help your body fight the cancer better, and it's designed for people with pancreatic ductal adenocarcinoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-11044246 on NIH RePORTER |
What this research studies
This research focuses on developing a combination treatment strategy for advanced pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDA). The approach involves using a novel chemotherapy drug, TGX-1214, which is formulated as a nanoemulsion, in conjunction with immune checkpoint inhibitors. The research team, comprising experts from the University of California at Davis, TargaGenix, and Northeastern University, aims to enhance the effectiveness of this treatment by increasing immune cell infiltration into tumors. Preliminary studies have shown promising results in reducing tumor growth in preclinical models.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced pancreatic ductal adenocarcinoma who have not responded to standard treatments.
Not a fit: Patients with early-stage pancreatic cancer or those who have not been diagnosed with pancreatic cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with advanced pancreatic cancer.
How similar studies have performed: Other research has shown success with similar combination therapies in treating pancreatic cancer, indicating a promising avenue for further exploration.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Mackenzie, Gerardo Guillermo — University of California at Davis
- Study coordinator: Mackenzie, Gerardo Guillermo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.